Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px
Person › Details

Jason Loveridge (4SC AG (FSE: VSC))

Loveridge, Jason (4SC 201609– CEO)

 

Organisation Organisation 4SC AG (FSE: VSC)
  Group 4SC (Group)
Products Product domatinostat (4SC-202)
  Product 2 drug development
     

4SC AG. (9/21/16). "Press Release: Dr Jason Loveridge Appointed New CEO of 4SC". Planegg-Martinsried.

Internationally experienced life sciences executive and investment professional will lead 4SC effective today


The Supervisory Board of 4SC AG (4SC, FSE Prime Standard: VSC) today appointed Dr Jason Loveridge as new CEO of 4SC. Jason Loveridge accepted the appointment and will assume the position effective today.

Jason Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia. He has more than 20 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies.

Dr Jason Loveridge comments: “At such a dynamic time in the field of oncology I am particularly excited to be joining 4SC as CEO – a company with a unique portfolio of epigenetic cancer assets, a highly experienced development team and strong investor support.

Given the increasing levels of interest from investors, clinicians and large pharma/biotech in epigenetic mechanisms in cancer, a real driver for my joining 4SC is a strong belief that its unique development expertise in this important area of cancer therapy and collection of epigenetic anti-cancer compounds – such as 4SC-202 – will be of real and significant interest to potential partners, particularly for their potential to be used in combination therapy. In addition, with resminostat soon in a pivotal Phase II study – as maintenance therapy for patients with cutaneous T-cell lymphoma – 4SC is well positioned for a potential first drug approval and initial revenues in the foreseeable future.

I see an exciting future for 4SC and am privileged to be part of what I am sure will be an important company in the cancer immunotherapy space.”

Dr Clemens Doppler, Chairman of 4SC’s Supervisory Board, adds: “It is a great pleasure to welcome Dr Jason Loveridge. For many years, he acted out of London, on behalf of companies, in Continental Europe, Asia and the US. With him, we have chosen a manager who not only has in-depth understanding of the life sciences sector but also brings substantial transactional experience in the sale and partnering of biotechnology assets to 4SC. We believe that Jason Loveridge perfectly complements the current team and will help to maximize value for 4SC’s shareholders.


– Press release ends –


Further information


About epigenetic cancer therapy

Epigenetic changes modify the activation of certain genes, but not the genetic code of DNA itself, causing activation or silencing of genes. This mechanism enables differentiated cells such as those in the lungs, nerves or skin to serve very different functions despite containing identical genetic code.

Epigenetic alterations are as important as genetic mutations in a cell’s transformation to cancer, and their manipulation holds great promise for cancer therapy. Epigenetic compounds such as 4SC’s resminostat and 4SC-202 may convert these epigenetic alterations back to normal. For example, treatment with epigenetic cancer compounds interrupts or combats the mechanism that is responsible for the onset of cancer, makes cancer cells visible to the body’s own immune system or renders them more responsive to immuno-oncological treatment.

Epigenetics is considered as a future growth market in the field of Oncology based on its significant promise as both a monotherapy and in combined approaches with immuno-oncology drugs and other therapeutic agents. In an October 2015 report by business information publisher Grand View Research, the worldwide epigenetics market was projected to generate revenues of US-$16 billion in 2022, up from US-$ 4 billion in 2014.


About 4SC

4SC (www.4sc.com) is a biotech company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.


Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.


4SC Corporate Communications & Investor Relations
Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73
Dr Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66

MC Services
Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40

The Ruth Group
Carol Ruth, cruth@theruthgroup.com, +1 646 536 7004

   
Record changed: 2019-06-09

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px


More documents for Jason Loveridge


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top